- Designated Head of Computational Biology Research Centre, Computational biology
Andrea Sottoriva is the designated Head of the Computational Biology Research Centre at Human Technopole.
Currently he is the Director of the Centre for Evolution and Cancer and the Deputy Head of the division of Molecular Pathology at the Institute of Cancer Research (ICR) in London. He is Professor of Cancer Genomics and Evolution and Principal Investigator of the Evolutionary Genomics and Modelling research group at the ICR.
Andrea’s research focusses on the development of new computational approaches to measure cancer evolution in patients, with the aim of predicting the future course of the disease. Andrea’s lab also integrates patient-derived experimental models and multiomics data, with evolutionary methods to design new treatment strategies that aim at preventing and controlling drug resistance.
After graduating in Computer Science at the University of Bologna in 2006, he obtained a master in Computational Sciences from the University of Amsterdam in 2008. During his studies, he worked in neutrino physics at the Department of Physics of the University of Bologna and at the Institute for Nuclear and High Energy Physics (NIKHEF) in the Netherlands as a research assistant.
In 2012 he completed his PhD in Computational Biology from the University of Cambridge, where he worked at the Cancer Research UK research centre.
After postdoctoral work at the University of Southern California, he started his lab at the ICR in 2013.
He authored several studies published in prestigious scientific journals, including Science, Nature Genetics and Cancer Discovery. Among his articles, Subclonal reconstruction of tumors by using machine learning and population genetics” (Nature Genetics, 2020), “Evolutionary dynamics of neoantigens in growing tumours” (Nature Genetics, 2020), “Detecting repeated cancer evolution from multi-region tumor sequencing data” (Nature Methods, 2018), “Longitudinal liquid biopsy and mathematical modelling of clonal evolution forecast waiting time to treatment failure in a phase II colorectal cancer clinical trial” (Cancer Discovery, 2018), e “Patient-derived organoids model treatment response of metastatic gastrointestinal cancers” (Science, 2018).